Piramal Pharma Receives Permanent Revocation of Closure Directions for Dahej Manufacturing Site

What Happened ?

Key Details

Regulatory Development:

• The order relates to Piramal Pharma’s Dahej manufacturing facility in Gujarat.
• Closure directions were originally issued by GPCB under Section 33A of the Water (Prevention and Control of Pollution) Act, 1974.
• The company had previously disclosed the matter on February 4, 12 and 14, 2026.
• Interim revocation had already been granted earlier.
• GPCB has now issued a permanent revocation order.
• The Dahej site is located at GIDC Dahej, Taluka Vagra, District Bharuch, Gujarat.
• Operations at the facility continue without interruption.

Note:

• The development removes a key regulatory overhang associated with the Dahej facility and confirms the site’s continued operational status.

Risk Analysis

Summary:

• The immediate regulatory issue has been resolved; however, manufacturing facilities remain subject to ongoing environmental and regulatory compliance requirements.

Key Risks:

• Future compliance obligations with environmental regulations remain applicable.
• Manufacturing operations continue to be monitored by regulatory authorities.
• Any future environmental non-compliance could result in fresh regulatory actions.
• The announcement does not disclose details of any conditions attached to the revocation order.

Worst Case Scenario:

• Any future environmental compliance lapse could trigger renewed regulatory scrutiny or operational restrictions.

Company Commentary

• The company has received an order from GPCB granting permanent revocation of the closure direction.
• Operations at the Dahej site continue in the normal course.
• Piramal Pharma remains committed to the highest standards of environmental compliance.
• The company requested stakeholders to take the update on record.